^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated:...in combination with paclitaxel protein-bound and carboplatin for the firstline treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations
Secondary therapy:
carboplatin + albumin-bound paclitaxel
